nach oben

Indian Journal of Hematology and Blood Transfusion

Erschienen in:

08.06.2019 | Original Article

Prognostic Impact of PPP2R5C Gene Expression in Adult Acute Myeloid Leukemia Patients with Normal Cytogenetics

verfasst von: Maha El Taweel, Rania M. Gawdat, Rafaat Abdelfattah

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Protein Phosphatase 2A (PP2A) is a crucial regulator of the cellular signalling pathways, proliferation, cell cycle checkpoints and apoptosis. The PPP2R5C gene encodes PP2A regulatory B56γ subunit. Malignant transformation may occur, if mRNA of PPP2R5C is functionally deregulated, structurally altered, decreased or overexpressed. Therefore, the purpose of the study was to examine PPP2R5C mRNA expression, evaluate its association with the different clinical and haematological parameters and determine its prognostic impact in Egyptian adult acute myeloid leukaemia patients with normal cytogenetics (CN-AML). Peripheral blood samples of 50 de novo CN-AML patients and 20 age- and gender-matched healthy controls were examined for PPP2R5C expression by Quantitative Real Time-Polymerase Chain Reaction. The expression levels of PPP2R5C mRNA were significantly higher in the CN-AML samples than in the control samples (P ≤ 0.001). There was a statistical significant difference between the low and high expression levels of PPP2R5C with regard to age (P = 0.005, r = − 0.447, P = 0.001). The patients with an unfavourable response to induction chemotherapy had significant higher PPP2R5C expression levels than those with a favourable response (P = 0.002). There was a significant influence of high PPP2R5C expression levels on the overall survival and progression free survival (P = 0.03, 0.026), respectively. PPP2R5C overexpression is an adverse prognostic factor which affects leukaemogenesis in the CN-AML, it may predict the disease progression and overall survival during the follow-up of the patients.

Shi Y (2009) Serine/threonine phosphatases: mechanism through structure. Cell 139:468–484. https://doi.org/10.1016/j.cell.2009.10.006 CrossRefPubMed

Heijman J, Dewenter M, El-Armouche A, Dobrev D (2013) Function and regulation of serine/threonine phosphatases in the healthy and diseased heart. J Mol Cell Cardiol 64:90–98. https://doi.org/10.1016/j.yjmcc.2013.09.006 CrossRefPubMed

Wlodarchak N, Xing Y (2016) PP2A as a master regulator of the cell cycle. Crit Rev Biochem Mol Biol 51(3):162–184. https://doi.org/10.3109/10409238.2016.1143913 CrossRefPubMedPubMedCentral

Yang J, Phiel C (2010) Functions of B56-containing PP2As in major developmental and cancer signalling pathways. Life Sci 87:659–666. https://doi.org/10.1016/j.lfs.2010.10.003 CrossRefPubMedPubMedCentral

Haesen D, Sents W, Lemaire K, Hoorne Y, Janssens V (2014) The basic biology of PP2A in hematologic cells and malignancies. Front Oncol 4:347. https://doi.org/10.3389/fonc.2014.00347 CrossRefPubMedPubMedCentral

Xu Y, Xing Y, Chen Y, Chao Y, Lin Z, Fan E, Yu JW, Strack S, Jeffrey PD, Shi Y (2006) Structure of the protein phosphatase 2A holoenzyme. Cell 127(6):1239–1251. https://doi.org/10.1016/j.cell.2006.11.033 CrossRefPubMed

Seshacharyulu P, Pandey P, Datta K, Batra SK (2013) Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett 335(1):9–18. https://doi.org/10.1016/j.canlet.2013.02.036 CrossRefPubMedPubMedCentral

Perrotti D, Neviani P (2013) Protein phosphatase 2A: a target for anti-cancer therapy. Lancet Oncol 14:e229–e238. https://doi.org/10.1016/s1470-2045(12)70558-2 CrossRefPubMedPubMedCentral

Eichhorn PJ, Creyghton MP, Bernards R (2009) Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 1795:1–15. https://doi.org/10.1016/j.bbcan.2008.05.005 CrossRefPubMed

10.

Ruvolo PP (2016) The broken “off” switch in cancer signalling PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance. BBA Clin 6:87–99. https://doi.org/10.1016/j.bbacli.2016.08.002 CrossRefPubMedPubMedCentral

11.

Shouse GP, Nobumori Y, Panowicz J, Liu X (2011) ATM-mediated phosphorylation activates the tumor-suppressive function of B56γ-PP2A. Oncogene 30:3755–3765. https://doi.org/10.1038/onc.2011.95 CrossRefPubMed

12.

Shouse GP, Cai X, Liu X (2008) Serine 15 phosphorylation of p53 directs its interaction with B56γ and the tumor suppressor activity of B56γ-specific protein phosphatase 2A. Mol Cell Biol 28:448–456. https://doi.org/10.1128/mcb.00983-07 CrossRefPubMed

13.

Li HH, Cai X, Shouse GP, Piluso LG, Liu X (2007) A specific PP2A regulatory subunit, B56γ, mediates DNA damage-induced de-phosphorylation of P53 at Thr55. EMBO J 26(2):402–411. https://doi.org/10.1038/sj.emboj.7601519 CrossRefPubMedPubMedCentral

14.

Lin SS, Bassik MC, Suh H, Nishino M, Arroyo JD, Hahn WC, Korsmeyer SJ, Roberts TM (2006) PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. J Biol Chem 281:23003–23012. https://doi.org/10.1074/jbc.m602648200 CrossRefPubMed

15.

Letourneux XC, Rocher G, Porteu F (2006) B56 containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX1and ERK. EMBO J 25(4):727–738. https://doi.org/10.1038/sj.emboj.7600980 CrossRefPubMedPubMedCentral

16.

Lee TY, Lai T-Y, Lin S-C, Wu C-W, Ni I-F, Yang Y-S, Hung L-Y, Law BK, Chiang C-W (2010) The B56γ3 regulatory subunit of protein phosphatase 2A (PP2A) regulates S phase-specific nuclear accumulation of PP2A and the G1 to S transition. J Biol Chem 285:21567–21580. https://doi.org/10.1074/jbc.m109.094953 CrossRefPubMedPubMedCentral

17.

Naetar N, Soundarapandian V, Litovchick L, Goguen KL, Sablina AA, Bowman-Colin C, Sicinski P, Hahn WC, DeCaprio JA, Livingston DM (2014) PP2A-mediated regulation of Ras signalling in G2 is essential for stable quiescence and normal G1 length. Mol Cell 54:932–945. https://doi.org/10.1016/j.molcel.2014.04.023 CrossRefPubMedPubMedCentral

18.

Peng XU, Virshup DM, Lee SH (2014) B56-PP2A regulates dynamics for mitotic chromosome alignment. J Cell Sci 127:4567–4573. https://doi.org/10.1242/jcs.154609 CrossRef

19.

Arriazu E, Pippa R, Odero MD (2016) Protein phosphatase 2A as a therapeutic target in acute myeloid leukemia. Front Oncol 6(78):1–14. https://doi.org/10.3389/fonc.2016.00078 CrossRef

20.

Suzuki HI, Matsuyama H, Noguchi M, Yao T, Komatsu N, Mano H, Sugimoto K, Miyazono K (2013) Computational dissection of distinct microRNA activity signatures associated with peripheral T cell lymphoma subtypes. Leukemia 27:2107–2111. https://doi.org/10.1038/leu.2013.121 CrossRefPubMed

21.

Deichmann M, Polychronidis M, Wacker J, Thome M, Naher H (2001) The protein phosphatase 2A subunit B gamma gene is identified to be differentially expressed in malignant melanomas by subtractive suppression hybridization. Melanoma Res 11:577–585. https://doi.org/10.1097/00008390-200112000-00004 CrossRefPubMed

22.

Chen W, Possemato R, Campbell KT, Plattner CA, Pallas DC, Hahn WC (2004) Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 5:127–136. https://doi.org/10.1016/s1535-6108(04)00026-1 CrossRefPubMed

23.

Zheng H, Chen Y, Chen S, Niu Y, Yang L, Li B, Lu Y, Geng S, Du X, Li Y (2011) Expression and distribution of PPP2R5C gene in leukemia. J Hematol Oncol 4:21–26. https://doi.org/10.1186/1756-8722-4-21 CrossRefPubMedPubMedCentral

24.

Falt S, Merup M, Gahrtonb G, Lamberta B, Wennborg A (2005) Identification of progression markers in B-CLL by gene expression profiling. Exp Hematol 33:883–893. https://doi.org/10.1016/j.exphem.2005.05.007 CrossRefPubMed

25.

World Medical Association (2008) Declaration of Helsinki. Ethical principles for medical research involving human subjects. The 59th WMA General Assembl, Seoul

26.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544 CrossRefPubMed

27.

O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Gore SD, Hall AC, Kropf P, Lancet J, Maness LJ, Marcucci G, Martin MG, Moore JO, Olin R, Peker D, Pollyea DA, Pratz K, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wang ES, Wieduwilt M, Gregory K, Ogba N (2017) Acute myeloid leukemia, version 3. 2017, Clinical practice guidelines in oncology. J Natl Compr Canc Netw 15(7):926–957. https://doi.org/10.6004/jnccn.2017.0116 CrossRefPubMed

28.

Dznelade I, He R, Wooly JF, Son MH, Sharobim MH, Greenberg SA, Gabra M, Langlois C, Rashid A, HakemA, Ibrahimova N, Arruda A, Lowenberg B, Valk PJ, Minden MD, Salmena L (2015) INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia. Leukemia 29(7):1485–1495. https://doi.org/10.1038/leu.2015.51 CrossRef

29.

Aly A, Shahin D, Azmy E (2012) Prognostic significance of Flt3 internal tandem duplication in Egyptian acute myeloid leukemia and normal cytogenetics. Comp Clin Pathol 21(5):1029–1035. https://doi.org/10.1007/s00580-011-1223-6 CrossRef

30.

El Gammal MM, Ebied GT, Madney YM, Abo-Elazm OM, Kelany AK, Torra OS, Radich JP (2019) Clinical impact of combined mutations in DNMT3A, FLT3-ITD and NPM1 among Egyptian acute myeloid leukemia patients. Clin Lymphoma Myeloma Leuk. https://doi.org/10.1016/j.clml.2019.02.001 CrossRefPubMed

31.

Huang X, Chen S, Shen Q, Yang L, Li B, Zhong L, Geng S, Du X, Li Y (2010) Analysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol 3:44. https://doi.org/10.1186/1756-8722-3-44 CrossRefPubMedPubMedCentral

32.

Tallman MS (2005) New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematol Am Soc Hematol Educ Prog 1:143–150. https://doi.org/10.1182/asheducation-2005.1.143 CrossRef

33.

EL-Zawahry H, Zeeneldin AA, Samra MA, Mattar MM, EL-Gammal MM, Abdel-Samee A, Darwish T (2007) Cost and outcome of treatment of adults with acute myeloid leukemia at the National Cancer Institute-Egypt. J Egypt Natl Cancer Inst 19:106–113

34.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Thomas Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien H-F, Wei AH, Löwenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424–447. https://doi.org/10.1182/blood-2016-08-733196 CrossRefPubMedPubMedCentral

35.

Gadhia PK, Patel MV, Vaniawala SN (2016) Role of cytogenetics evaluation in diagnosis of AML. Am J Biomed Life Sci 4(6):98–102. https://doi.org/10.11648/j.ajbls.20160406.13 CrossRef

36.

Janssens V, Rebollo A (2012) The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr Mol Med 12:268–287. https://doi.org/10.2174/156652412799218930 CrossRefPubMed

37.

Hu C, Yu M, Ren Y, Li K, Maggois DM, Mei C, Ye L, Wei J, Jin J, Zhuangs Z, Tong H (2017) PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation. Sci Rep 7:2894–2908. https://doi.org/10.1038/s41598-017-030584 CrossRefPubMedPubMedCentral

38.

Lai TY, Yen CJ, Tsai HW, Yang YS, Hong WF, Chiang CW (2016) The B56γ3 regulatory subunit-containing protein phosphatase 2A out competes Akt to regulate p27KIP1 subcellular localization by selectively dephosphorylating phospho-Thr157 of p27KIP1. Oncotarget 7:4542–4558. https://doi.org/10.18632/oncotarget.6609 CrossRefPubMed

39.

Ayatollahi H, Rostami E, Sadeghian MH, Keramati MR, Zeinali E (2016) Expression level of the PPP2R5C gene in patients with acute myeloid leukemia and chronic myeloid leukemia. J Biomed 1(1):e5334. https://doi.org/10.17795/jbm-5334 CrossRef

40.

Benton CB, Ruvolo VR, Konopleva M, Palla SL, Nogueras-Gonzalez G, McQueen T, Kornblau SM, Andreeff M, Ruvolo PP (2015) Expression of differential protein phosphatase 2A subunit isoforms correlates with survival in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15: Supplement 2:S22

41.

Kawahara E, Maenaka S, Shimada E, Nishimura Y, Sakurai H (2013) Dynamic regulation of extracellular signal-regulated kinase (ERK) by protein phosphatase 2A regulatory subunits in nuclei induces cell migration. PLoS ONE 8(5):e63729. https://doi.org/10.1371/journal.pone.0063729 CrossRefPubMedPubMedCentral

42.

Ito A, Kataoka TR, Watanabe M, Nishiyama K, Mazaki Y, Sabe H, Kitamura Y, Nojima H (2000) A truncated isoform of the PP2AB56 subunit promote cell motility through paxillin phosphorylation. EMBO J 19:562–571. https://doi.org/10.1093/emboj/19.4.562 CrossRefPubMedPubMedCentral

43.

Janssens V, Goris J, Van Hoof C (2005) PP2A: the expected tumor suppressor. Curr Opin Genet Dev 15:34–41. https://doi.org/10.1016/j.gde.2004.12.004 CrossRefPubMed

44.

Ito A, Koma Y, Watabe K, Nagano T, Endo Y, Nojima H, Kitamara Y (2003) A truncated isoform of the protein phosphatase 2A B56 regulatory subunit may promote genetic instability and cause tumor progression. Am J Pathol 162:81–91CrossRefPubMedPubMedCentral

45.

Ruvolo PP (2019) Role of protein phosphatases in the cancer microenvironment. Biochim Biophys Acta Mol Cell Res 1866(1):144–152. https://doi.org/10.1016/j.bbamcr.2018.07.006 CrossRefPubMed

46.

Cristobal I, Gracia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD (2011) PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 25:606–614. https://doi.org/10.1038/leu.2010.294 CrossRefPubMed

47.

Chen Y, Liu S, Shen Q, Zha X, Zheng H, Yang L, Chen S, Wu X, Li B, Li Y (2013) Differential gene expression profiles of PPP2R5C-siRNA-treated malignant T cell. DNA Cell Biol 10:573–581. https://doi.org/10.1089/dna.2013.2138 CrossRef

48.

Shen Q, Liu S, Chen Y, Yang L, Chen S, Wu X, Li B, Lu Y, Kanger Zhu K, Li Y (2013) Proliferation inhibition and apoptosis induction of imatinib resistant chronic myeloid leukemia cells via PPP2R5C down-regulation. J Hematol Oncol 6:64–75. https://doi.org/10.1186/1756-8722-6-64 CrossRefPubMedPubMedCentral

49.

Liu S, Shen Q, Chen Y, Zeng C, Cao C, Yang L, Chen S, Wu X, Li B, Li Y (2015) Alteration of gene expression profile following PPP2R5C knockdown may be associated with proliferation suppression and increased apoptosis of K56 cells. J Oncol Heamatol 8:34–37. https://doi.org/10.1186/s13045-015-0125-5 CrossRef

50.

Sangodkar J, Farrington CC, McClinch K, Galsky MD, Kastrinsky DB, Narla G (2016) All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase. FEBS J 283:1004–1024. https://doi.org/10.1111/febs.13573 CrossRefPubMed

Titel: Prognostic Impact of PPP2R5C Gene Expression in Adult Acute Myeloid Leukemia Patients with Normal Cytogenetics
verfasst von: Maha El Taweel
Rania M. Gawdat
Rafaat Abdelfattah
Publikationsdatum: 08.06.2019
Verlag: Springer India
Erschienen in: Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2020
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-019-01142-5

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Prognostic Impact of PPP2R5C Gene Expression in Adult Acute Myeloid Leukemia Patients with Normal Cytogenetics

Abstract

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Health-Related Quality of Life and Burden of Fatigue in Chinese Patients with Immune Thrombocytopenia: A Cross-Sectional Study

A Prospective Observational Multi-institutional Study on Invasive Fungal Infections Following Chemotherapy for Acute Myeloid Leukemia (MISFIC Study): A Real World Scenario from India

Pseudothrombocytopenia in Patients with Scrub Typhus Infection

Priapism in Childhood B-Cell Acute Lymphoblastic Leukemia: A Rare Presentation

All That Lights-Up is not Lymphoma

Application of Perioperative Transfusion Trigger Score in Patients Undergoing Surgical Treatment of Malignant Tumor

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie